ArticleInternational journal of clinical and experimental pathology2017
Changes of Th1/Th2 cytokines in patients with primary hepatocellular carcinoma after ultrasound-guided ablation.
Article in International journal of clinical and experimental pathology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 18 citations in OpenAlex.
- Dynamics of peripheral immune signature identified by multi-omics and its impact on recurrence after radiofrequency ablation of hepatocellular carcinoma.Frontiers in immunology · 2026Article
- Growth differentiation factor 11 modulates metabolism, mitigating the pro-tumoral behavior provided by M2-like macrophages in hepatocellular carcinoma-derived cells.World journal of gastroenterology · 2025Article
- The Synergistic Effect of Interventional Locoregional Treatments and Immunotherapy for the Treatment of Hepatocellular Carcinoma.International journal of molecular sciences · 2023Review
- An Inflammation-Associated Prognosis Model for Hepatocellular Carcinoma Based on Adenylate Uridylate- (AU-) Rich Element Genes.Mediators of inflammation · 2023Article
- Study on Changes in Immune Function After Microwave Ablation of Papillary Thyroid Microcarcinoma.Cancer management and research · 2022Article
- HSPB11 is a Prognostic Biomarker Associated with Immune Infiltrates in Hepatocellular Carcinoma.International journal of general medicine · 2022Article
- Integrated Multi-Omics Data Analysis Reveals Associations Between Glycosylation and Stemness in Hepatocellular Carcinoma.Frontiers in oncology · 2022Article
- Ficolin-2: A potential immune-related therapeutic target with low expression in liver cancer.Frontiers in oncology · 2022Article
- Combinatory local ablation and immunotherapies for hepatocellular carcinoma: Rationale, efficacy, and perspective.Frontiers in immunology · 2022Review
- Immunological Markers, Prognostic Factors and Challenges Following Curative Treatments for Hepatocellular Carcinoma.International journal of molecular sciences · 2021Review
- Immune Responses Following Locoregional Treatment for Hepatocellular Carcinoma: Possible Roles of Adjuvant Immunotherapy.Pharmaceutics · 2021Review
- Elevated Neddylation Pathway Promotes Th2 Cells Infiltration by Transactivating STAT5A in Hepatocellular Carcinoma.Frontiers in oncology · 2021Article
- Recent Advances: The Imbalance of Immune Cells and Cytokines in the Pathogenesis of Hepatocellular Carcinoma.Diagnostics (Basel, Switzerland) · 2020Review
- Combined locoregional-immunotherapy for liver cancer.Journal of hepatology · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Liver cancer is a malignancy of the digestive system and has a high morbidity and mortality rate. Local intervention has become a viable option in identifying liver treatment. The aim of the present study was to analyze the changes of Th1/Th2 cytokines in patients with primary hepatocellular carcinoma (HCC) after radiofrequency ablation (RFA) treatment. 26 patients with stage III-IV liver cancers and 25 healthy controls were selected to participate in the study. HCC patients were initiated with RFA treatment and the serum levels of alpha fetoprotein (AFP) and Th1/Th2 cytokines were valued. We found that with the level of AFP decreased, the levels of Th1 cytokines including interleukin-2 (IL-2), tumor necrosis factor-α (TNF-α) and interferon-γ (IFN-γ) were significantly increased after treatment with RFA (
Indexed as
Identifiers
31966730PMC6965388W3004808849What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.